Resonant pioneers blood tests for neurodegenerative disease. By detecting cell-free DNA from dying neurons, our technology aims to detect and monitor neurodegeneration, potentially before clinical symptoms emerge. We are currently validating tests for Alzheimer’s, Parkinson’s, and ALS in large-scale human studies, with plans to expand to other conditions like traumatic brain injury and multiple sclerosis. Visit Our Website

Wasatch BioLabs is a native-read sequencing lab driving innovation from biomarker discovery to clinical implementation. With proprietary protocols, long-read technologies, and bioinformatics expertise, WBL delivers scalable, high-throughput solutions—empowering researchers, biopharma, and other industry partners to advance precision medicine across oncology, neurology, and beyond. Visit Our Website

Pathogen is transforming how we detect and monitor infectious diseases. With proprietary targeted long-read sequencing, we identify and quantify pathogen-derived DNA in the blood to support earlier, more accurate detection of infection biomarkers often missed by traditional methods. Our flexible platform supports diagnostic development for Lyme disease and a wide range of other infectious conditions.

Founded by women, eXXperts brings precision to women’s health through targeted native DNA sequencing. Specializing in the detection of biomarkers for underdiagnosed conditions like endometriosis and gynecologic cancers, eXXperts also develops forensic applications of its technology to distinguish menstrual from peripheral blood, aiding investigations of crimes against women.